Oncology Drug Crash Course: Teclistamab-cqyv (Tecvayli)
Amanda Warner, MS, BSN, RN, OCN, who is manager of research informatics & real world evidence with Florida Cancer Specialists & Research Institute, provides an in-depth look at teclistamab in a downloadable fact sheet.
Complex Cancer Cases: Veno-Occlusive Disease in a Pediatric Patient Receiving Nontransplant-Associated Chemotherapy
Veno-occlusive disease or sinusoidal obstruction syndrome is commonly associated as a complication with transplant in pediatric patients but can also be seen with chemotherapy alone.
Wheatley and Gopalsami Highlight the Value of Interdisciplinary Collaboration in HSCT Care
Tia Wheatley, DNP, RN, AOCNS, BMTCN, and Shivani Gopalsami, RN, MSN, ANP-BC, AOCNP, discuss the benefits and challenges of multidisciplinary collaboration in hematopoietic stem cell transplant care.
Patients With De Novo or Late Recurrent Metastatic HR+ Breast Cancer Derive OS Benefit From Ribociclib/Letrozole
A subgroup analysis showed that patients with hormone receptor–positive, HER2-negative advanced breast cancer who had de novo metastatic disease or late recurrence from neoadjuvant therapy achieved better outcomes with ribociclib plus letrozole.
Encorafenib/Cetuximab/Binimetinib Triplet Safe and Effective in BRAF V600E–Mutant mCRC
Treatment with encorafenib in combination with cetuximab and binimetinib was active with a manageable safety profile in the first-line setting for patients with BRAF V600E–mutated metastatic colorectal cancer.
Brenda Martone Highlights Nursing Considerations With Darolutamide in Prostate Cancer
Brenda Martone MSN, ANP-BC, AOCNP, discusses what nurses need to know about safely treating patients with darolutamide.
Extended Anastrozole Therapy Improves DFS in Postmenopausal Patients With HR+ Breast Cancer
Extending anastrozole treatment to 10 years in postmenopausal women with hormone receptor–positive breast cancer who have no evidence of disease after 5 years of standard-of-care treatments.
Enzalutamide Associated With Lower Metastases Risk Vs Leuprolide Alone in High-Risk nmHSPC
Enzalutamide plus leuprolide lowered the risk of metastases or death by 58% compared with placebo plus leuprolide.
Best Practices on Managing AEs With Darolutamide Plus ADT/Docetaxel in mHPSC
Data presented during the ONS Annual Congress offers guidance for nurses caring for patients receiving darolutamide, docetaxel, and androgen deprivation therapy.
Ocular Toxicity Management Is Paramount for Mirvetuximab Soravtansine Treatment
Managing ocular-related adverse effects with mirvetuximab soravtansine is key to helping patients with ovarian cancer stay on treatment.
Cilta-Cel AEs Remain Consistent and Manageable for Patients with Multiple Myeloma
An analysis of the cilta-cel safety profile yielded promising results, according to nurse investigators.
Intermittent Dosing Strategy Helps Thrombocytopenia Related to MDM2 Inhibitor Milademetan
Milademetan, a MDM2 inhibitor, is associated with thrombocytopenia. An intermittent dosing schedule may help mitigate that adverse event.
Multiple Myeloma Treatment Evolution Expands Need for APP Education
Beth Faiman, PhD, MSN, APRN-BC, AOCN, discusses the growing need for advanced practitioner provider education and her role with the NP/PA center of excellence.
Pembrolizumab in Addition to Cisplatin and Gemcitabine Boosts Overall Survival in Advanced Biliary Tract Cancer
Patients who received pembrolizumab plus cisplatin and gemcitabine achieved a median overall survival of 12.7 months, compared with 10.9 months with cisplatin and gemcitabine alone.
Nursing Panel Shares Experiences in Managing Toxicities in Renal Cell Carcinoma
Sarah Yenser Wood, RN, MSN, ANP, AOCNP, leads a nursing panel on adverse event management in renal cell carcinoma.
Polatuzumab Vedotin Approved in Combination with R-CHP for Treatment-Naïve DLBCL, High-Grade B-Cell Lymphoma
Polatuzumab vedotin has been approved in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone for previously untreated diffuse large B-cell lymphoma.
Perioperative Durvalumab Plus Neoadjuvant Chemotherapy Outperforms Placebo in Resectable NSCLC
The pathologic complete response rate with durvalumab was 17.2% vs 4.3% with placebo, reflecting an absolute difference of 12.9%.
A Multidisciplinary Approach Improves a Patient’s Experience With Colon Cancer
Early coordination with multiple specialty teams can maximize outcomes and improve quality of life for patients with complex metastatic disease.
Meghan Berkenstock on Managing Ocular Toxicities With ADCs in Cervical and Ovarian Cancers
Meghan K. Berkenstock, MD, discusses the growing need for strong collaboration between ophthalmologists and gynecologic oncology care teams.
Perspectives on Best Practices in Caring for Patients With Pancreatic Cancer and Cholangiocarcinoma
Patients with unresectable pancreatic cancers and cholangiocarcinoma face poor prognoses, but systemic treatment continues to evolve.
Neoadjuvant Olaparib Leads to High Optimal Resection Rate in BRCA-Mutated Ovarian Cancer
With a follow-up of 11.7 months, the estimated 12-month progression-free survival rate was 81% in patients who received neoadjuvant olaparib for BRCA-positive ovarian cancer.
Cemiplimab Shows Clinical Benefit for Patients With PD-L1+ NSCLC and Brain Metastases
At a median follow-up of 33.3 months, the median overall survival was not evaluable with cemiplimab, vs 20.7 months with chemotherapy alone, in this patient subset.
Adagrasib Garners 68% ORR in Patients With KRAS G12C-Mutated Non–Small Cell Lung Cancer
In a subset of patients with KRAS G12C–mutated non–small cell lung cancer, adagrasib yielded an overall response rate of 68%.
Hematologic Oncology Undergoes Transformation With Drug Updates and Approvals
Kathryn Maples, PharmD, BCOP, highlights recent approvals, and updated labeling, along with drug removals, across leukemia, lymphoma, and multiple myeloma.
Considerations for Premenopausal Women With TNBC
Triple-negative breast cancer often occurs in women younger than 40.
Zev Wainberg on Combination Chemotherapy Regimens in Metastatic Pancreatic Cancer
Zev A. Wainberg, MD, discusses the implications of the findings from the phase 3 NAPOLI 3 trial for patients with metastatic pancreatic ductal adenocarcinoma.
Preparing Patients for CAR T-Cell Therapy With Confidence
As the therapy continues to evolve, best nursing practices become more nuanced.
Pembrolizumab With or Without Chemotherapy Continues to Show Survival Benefit Over Cetuximab Plus Chemotherapy in Recurrent/Metastatic HNSCC
Patients with head and neck squamous cell carcinoma continued to displayed a survival benefit with pembrolizumab at a 4-year follow-up.
Sacituzumab Govitecan Receives Indication for Unresectable, Locally Advanced or Metastatic HR+/HER2- Breast Cancer
The FDA has approved sacituzumab govitecan-hziy for patients with unresectable locally advanced or metastatic hormone receptor-positive, HER2-negative breast cancer.
Ibrutinib Plus Prednisone Does Not Improve Response Rates in cGVHD
First-line ibrutinib plus prednisone missed the primary endpoint in the phase 3 iNTEGRATE trial by not improving the response rate in patients with chronic graft-versus-host-disease compared with placebo plus prednisone.
Neoadjuvant Durvalumab Combination Misses Mark in EGFR+ NSCLC
Durvalumab Garners Similar OS, Albeit Varied PFS, Outcomes in EGFR+ and EGFR-Wildtype NSCLC Subgroups
Quizartinib Extends Overall Survival Across Multiple Subgroups in FLT3-ITD+ AML
Repotrectinib Showcases Early Intracranial Responses in Select ROS1+ NSCLC
2 Clarke Drive Cranbury, NJ 08512